Information technology services industry
Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company, reported its financial results for the quarter ended March 31, 2023, and announced that it has entered into a definitive agreement to be acquired by Merck for $200.00 per share in cash, totaling approximately $10.8 billion. The transaction is
Cybernet Data Systems Inc.
Aytu BioPharma, a biopharmaceutical company, has appointed Christopher Brooke as its new Chief Operating Officer. Brooke brings over 20 years of general management experience in healthcare, having held various roles of increasing responsibility at companies such as AmerisourceBergen, Centocor (Johnson & Johnson), and MedImmune (AstraZeneca). His rare disease experience includes
Cybernet Data Systems Inc.
BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced its financial results for the third quarter ended September 30, 2022. The company also provided a corporate update, highlighting its commitment to ALS patients and its belief in the potential of NurOwn to
Cybernet Data Systems Inc.
Seagen Inc. announced positive topline results from the pivotal phase 2 MOUNTAINEER clinical trial investigating TUKYSA(R) (tucatinib) in combination with trastuzumab in patients with previously treated HER2-positive metastatic colorectal cancer. The combination of tucatinib and trastuzumab showed a 38.1% confirmed objective response rate (cORR) with a median duration
Cybernet Data Systems Inc.
ImmunoGen, a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the US Food and Drug Administration (FDA) has accepted and filed the Biologics License Application (BLA) for mirvetuximab soravtansine monotherapy in patients with folate receptor alpha (FRĪ±)-high platinum-resistant ovarian cancer
Vaccines
Valneva SE and Pfizer Inc announced positive Phase 2 paediatric results for their Lyme disease vaccine candidate, VLA15, on April 26, 2022. The new data plan to include paediatric participants in their upcoming Phase 3 trial, evaluating VLA15 in adults and children aged 5 years and above. The Phase 2
Vaccines
Amnesty International has called on institutional investors to use their influence to ensure that supplies of urgently needed life-saving vaccines reach low- and lower-middle-income countries. The organization has criticized pharmaceutical companies for monopolizing technology, blocking and lobbying against the sharing of intellectual property, charging high prices for vaccines, and prioritizing
Vaccines
A subgroup analysis of a global phase 3 randomized clinical trial has found that the BNT162b2 mRNA COVID-19 vaccine was safe and efficacious against infection, hospitalization, and death in individuals with a history of cancer. The study, conducted by researchers at Pfizer, included 46,429 participants aged 12 years and
COVID-19
The global regenerative medicine market size was estimated at $16.69 billion in 2021 and is projected to grow at a CAGR of 20.03% to reach $49.94 billion by 2027. The market is expected to be driven by increasing adoption of stem cell technologies, gene therapies, and tissue
COVID-19
The global regenerative medicine market size was estimated at USD 16.69 billion in 2021 and is expected to reach USD 20.01 billion in 2022. This growth is driven by increasing adoption of stem cell technologies, gene therapies, and tissue engineering, as well as technological advancements in regenerative medicine
Vaccines
As of March 24, nearly 256 million people in the United States have received at least one dose of a COVID-19 vaccine, representing 76.8% of the total population. However, with the surge of the Omicron variant BA.2, concerns about the effectiveness of current vaccines and the need for
Vaccines
A series of five cases of Herpes Zoster occurring after vaccination with a nucleoside-modified messenger RNA (mRNA) COVID-19 vaccine has been reported by researchers at the Hospital Center University of Lille. The cases do not establish causality between COVID-19 vaccination and Herpes Zoster, but local vaccine-induced immunomodulation may be involved.
